Addex Therapeutics Ltd banner
Financial profile · Q1 FY2026

A clinical-stage biotech with irregular income and equity-funded development

Across the multi-year record, collaboration-related income has been small and uneven relative to recurring operating and research costs. Equipment spending is minimal, but ongoing losses mean development relies on available cash and equity financing; one-off transactions and associate results can also make net income fluctuate.

What is developing

For the quarter ended March 31, 2026, the operating loss narrowed as reported operating costs fell, while the net loss widened because the share of associates’ losses increased. This separates a cost improvement at Addex from the larger loss contribution of its investment and does not yet change the underlying loss-making, externally funded model.

What matters next

Whether the next reported cash balance is supported by new equity proceeds while operating cash outflow moderates.

CHF
Metric FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
400k 499.9k 6.7m 2.8m 3.9m 3.2m 1.4m 1.6m 410k 172.9k
(3.5m) (3.7m) (8.1m) (17.4m) (16.1m) (18.7m) (22m) (3.9m) (3.2m) (3m)
(1.1m) (1.1m) (3.2m) (5m) (5.7m) (5.8m) (7.3m) (2.7m) (2.3m) (2.3m)
R&D
(2.4m) (2.6m) (4.9m) (12.4m) (10.4m) (12.8m) (14.6m) (1.2m) (851.2k) (671.7k)
(25.8k) (15.3k) (2.9k) (9.7k) (19.3k) (27.2k) (31.6k) (25.4k) (3.8k) —
(3.1m) (3.2m) (1.4m) (14.6m) (12.2m) (15.5m) (20.5m) (2.2m) (2.8m) (2.8m)
(19.8k) (45.4k) (220.2k) (176.5k) (615.3k) 308k (284k) (257.2k) (2.2m) (4m)
6.9k 200 134.3k 128.5k 69.5k 63k 48.9k 3.9k 3.6k 2.4k
11.8k 0 — — — — — — — —
(3.1m) (3.3m) (1.6m) (14.8m) (12.9m) (15.2m) (20.8m) (2.5m) (4.9m) (6.8m)
0 0 — 0 — 0 0 0 0 0
(3.1m) (3.3m) (1.6m) (14.8m) (12.9m) (15.2m) (20.8m) (2.5m) (4.9m) (6.8m)
(3.1m) (3.3m) (1.6m) (14.8m) (12.9m) (15.2m) (20.8m) (10.6m) 7.1m (6.7m)
(0.28) (0.25) (0.07) (0.56) (0.48) (0.45) (0.46) (0.14) 0.07 (0.06)